FX 322
Alternative Names: FX-322Latest Information Update: 11 Jan 2024
Price :
$50 *
At a glance
- Originator Frequency Therapeutics
- Developer Korro Bio
- Class Small molecules
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sensorineural hearing loss
Most Recent Events
- 13 Feb 2023 Discontinued - Clinical-Phase-Unknown for Sensorineural hearing loss in Germany (Intratympanic)
- 13 Feb 2023 Discontinued - Phase-I for Sensorineural hearing loss in Australia (Intratympanic)
- 13 Feb 2023 Discontinued - Phase-II for Sensorineural hearing loss (In the elderly, In adults) in USA (Intratympanic)